BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  ThromboGenics Struggles to Find Patients for Phase II Eye Disease Trial

  Resources redirected to progress new drug candidates to clinic in H1 2018.

  December 8, 2017

   · 

  4 min read
• 

  Policy

  Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

  At the meeting, the panel voted 15 to 0 that patients with interstitial cystitis and patients with bladder pain syndrome should be combined in clinical trials.

  December 8, 2017

   · 

  6 min read
• Drug Development

  Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium

  Elacestrant recently received Fast Track designation from the U.S. Food and Drug Administration.

  December 8, 2017

   · 

  7 min read
• Biotech Bay

  Marrone Bio Innovations Announces the Availability of Amplitude Biofungicide for White Mold Control in the 2018 Growing Season

  Amplitude is an effective new tool for controlling white molds in pulse, root and oilseed crops, as well as soil diseases like Rhizoctonia in large acre crops.

  December 8, 2017

   · 

  5 min read
• BioForest

  Adaptive Biotechnologies and Collaborators to Highlight Clinical Relevance of Measuring Residual Disease in Blood Cancers at ASH 2017

  Data presented at ASH will demonstrate how Adaptive’s clonoSEQ Assay to measure MRD, the cancerous cells remaining in the body after treatment, can inform clinical care in patients with B and T cell lymphoid malignancies.

  December 8, 2017

   · 

  11 min read
• Biotech Beach

  Peregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred Stock

  The quarterly dividend on the Series E Preferred Stock is payable on January 2, 2018 to holders of record at the close of business on December 18, 2017

  December 8, 2017

   · 

  2 min read
• Bio NC

  Fennec Announces Proposed Public Offering of Common Shares

  In addition, Fennec intends to grant the underwriters a 30-day option to purchase up to an additional 15% of its common shares offered in the public offering.

  December 8, 2017

   · 

  4 min read
• Biotech Bay

  Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 ASH Annual Meeting

  Rigel Pharma today announced that the one-year efficacy and safety results from its FIT Phase 3 clinical program of fostamatinib for chronic or persistent immune thrombocytopenia (ITP) will be featured in an oral presentation at the 2017 ASH Annual Meeting.

  December 8, 2017

   · 

  4 min read
• Biotech Bay

  Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in Singapore and New Zealand Covering Treatment of Parkinson’s LID

  Both patents are titled “Treatment of Motor Symptoms and Movement Disorder Side Effects Associated with Parkinson’s disease treatments,” and are valid into 2033.

  December 8, 2017

   · 

  4 min read
• BIOCAD Demonstrated the Use of Hela Cells in Oncology Research

  BioCad demonstrated how “immortal” HeLa cells are used all over the world in oncology research and in development of anti-cancer drugs.

  December 8, 2017

   · 

  2 min read